Exelixis v. MSN Laboratories: Cabozantinib ANDA Patent Battle — Plaintiff Prevails
Exelixis secured final judgment against MSN Laboratories in the Delaware District Court, blocking MSN’s generic cabozantinib ANDA product from U.S. market entry until at least January 15, 2030. The 828-day Hatch-Waxman litigation turned on infringement of three patents covering CABOMETYX®, an oncology blockbuster.
Exelixis locks out MSN’s generic cabozantinib until 2030
Exelixis, Inc. filed suit on July 18, 2022, in the District of Delaware against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc., asserting infringement of four patents covering cabozantinib under 35 U.S.C. § 271(e)(2) — the Hatch-Waxman ANDA pathway. The accused product was MSN’s proposed generic version of CABOMETYX® (cabozantinib (S)-malate tablets, 20 mg, 40 mg, and 60 mg), covered by ANDA No. 213878. CABOMETYX® is a multi-kinase inhibitor approved for renal cell carcinoma and hepatocellular carcinoma, representing a substantial portion of Exelixis’ commercial revenue.
Final judgment was entered on October 23, 2024, in favor of Exelixis on three of the four asserted patents: claim 4 of the ‘439 patent, claim 3 of the ‘440 patent, and claim 2 of the ‘015 patent. MSN prevailed on the infringement claim relating to claim 3 of the ‘349 patent — though Exelixis also won on MSN’s invalidity counterclaim for that patent, meaning the ‘349 patent survived as valid even if not infringed by the ANDA product. Judge Andrews issued a permanent injunction blocking MSN from commercializing the ANDA product in the U.S. until at least January 15, 2030, the expiry date of the three infringed patents.
At 828 days, the case reflects the typical complexity of multi-patent Hatch-Waxman trials in Delaware, though the split verdict on the ‘349 patent suggests contested claim scope around one aspect of cabozantinib’s composition or method claims. The public record does not disclose whether settlement discussions occurred, nor the precise technical basis on which MSN succeeded on the ‘349 infringement claim. Attorneys’ fees proceedings remain open, and any exceptional-case motion under § 285 could extend the financial stakes of this dispute beyond the judgment itself.
Filing to Judgment on the merits for Plaintiff in 828 days
828 days — above the median duration for ANDA patent cases in Delaware District Court
Final judgment for Exelixis: what the split verdict means for both parties
Hatch-Waxman infringement: what § 271(e)(2) means here
Under 35 U.S.C. § 271(e)(2), filing an ANDA with a Paragraph IV certification is itself an act of infringement. Exelixis did not need to show MSN had sold a single tablet — only that ANDA No. 213878 covered a product that would infringe the asserted claims. The court found infringement of three specific claims across the ‘439, ‘440, and ‘015 patents, triggering the mandatory § 271(e)(4) remedies: delayed FDA approval and a permanent injunction.
ANDA / § 271(e)(2) infringementExelixis retains CABOMETYX® exclusivity through January 2030
The judgment effectively shields CABOMETYX® from MSN’s generic competition for the life of the ‘439, ‘440, and ‘015 patents. The FDA cannot grant final approval to ANDA No. 213878 before January 15, 2030, including any patent term extensions. All three patents also survived MSN’s invalidity counterclaims. Exelixis did not prevail on the ‘349 infringement claim, but that outcome has no practical commercial impact given the injunction already secured on the remaining three patents.
Generic entry blocked to 2030MSN’s U.S. generic launch blocked; ‘349 partial win offers limited relief
MSN succeeded in defeating the infringement claim on the ‘349 patent’s claim 3, but failed to invalidate any of the four asserted patent claims. The practical result is unchanged: MSN cannot commercialize its cabozantinib ANDA product in the U.S. until 2030 at the earliest. MSN retains the option to appeal the infringement findings on the three lost patents, and the ‘349 non-infringement finding may inform future ANDA design-around strategies, though the path to early market entry looks narrow.
Generic launch delayed to 2030Oncology ANDA challengers face strengthened multi-patent barriers
This outcome reinforces how patent portfolio depth — multiple overlapping claims across compositions, formulations, and methods — can insulate a branded oncology drug from ANDA competition even when one claim falls short. Generics targeting CABOMETYX® or similar kinase inhibitors will need to navigate claim-by-claim FTO analysis across all listed patents. The surviving invalidity findings on all four patents signal that MSN’s invalidity arguments failed comprehensively, which may discourage near-term follow-on ANDA challenges by other filers.
Multi-patent portfolio strategy validatedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Exelixis, Inc. | Company | Oncology biopharmaceutical company — holder of cabozantinib (CABOMETYX®) patent portfolioSearch in Eureka ↗ |
| Defendant | MSN Laboratories Private Limited | Individual | Indian generic pharmaceutical manufacturer seeking U.S. ANDA approval for cabozantinib tabletsSearch in Eureka ↗ |
| Co-Defendant | MSN Pharmaceuticals, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Exelixis, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Exelixis, Inc.Search in Eureka ↗ |
| Defendant counsel | Dominick T. Gattuso | Attorney | Counsel for MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Defendant law firm | Heyman Enerio Gattuso & Hirzel, LLP | Law Firm | Representing MSN Laboratories Private LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Richard G. Andrews | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The final judgment is structured claim-by-claim across four patents, reflecting Judge Andrews’ precise adjudication of each Paragraph IV assertion. Exelixis prevailed on three patents’ specific claims while MSN secured non-infringement on a single claim of the ‘349 patent — yet MSN’s invalidity counterclaims failed on all four patents. The § 271(e)(4)(A) and (B) remedies automatically flow from the infringement findings, mandating both delayed FDA approval and a permanent injunction through January 15, 2030. The split result on infringement versus invalidity of the ‘349 patent is notable: the patent is valid but not infringed by this ANDA product, which may have implications for future challenge strategies.
US11298349B2 — cabozantinib compositions and oncology treatment methods
US11298349B2 (application number US17/170275) is one of four patents asserted by Exelixis in this Hatch-Waxman litigation, all covering aspects of cabozantinib — a multi-kinase inhibitor marketed as CABOMETYX® for renal cell carcinoma and hepatocellular carcinoma. The patents-in-suit collectively cover compositions, formulations, and methods of use relating to cabozantinib (S)-malate, with claims drafted at the specific dependent-claim level to target ANDA products precisely. The ‘439, ‘440, and ‘015 patents were found infringed; the ‘349 patent survived invalidity challenges though its claim 3 was not infringed by MSN’s ANDA product.
Cabozantinib is a high-value oncology asset, and the patent portfolio surrounding it reflects a layered prosecution strategy designed to maximize ANDA barriers. The fact that Exelixis asserted specific dependent claims — rather than broader independent claims — suggests deliberate claim selection to optimize infringement read-on against MSN’s tablet formulation. For competitors in the kinase inhibitor or oncology small-molecule space, this case illustrates how overlapping claim families across multiple patents can sustain market exclusivity even when individual claims are challenged or partially defeated.
Should your team run an FTO against the Exelixis cabozantinib patent portfolio?
Any pharmaceutical company or ANDA filer considering a generic or follow-on version of cabozantinib tablets should treat this case as a direct signal to conduct rigorous freedom-to-operate analysis. The Delaware court found that specific formulation and composition claims across three patents read on MSN’s proposed tablets — meaning claim-by-claim FTO is essential, not just a portfolio-level review. The ‘349 non-infringement finding also shows that careful claim mapping can reveal narrow non-infringing pathways, but those must be identified before ANDA filing.
PatSnap Eureka’s FTO Search Agent can map your proposed formulation against the full Exelixis cabozantinib patent family, identify claim overlaps at the dependent-claim level, and flag related continuation and divisional applications that may not yet be listed in the Orange Book. For R&D teams designing cabozantinib generics or kinase inhibitor analogs, Eureka’s claim-charting tools can accelerate the FTO process and help prioritize invalidity arguments before committing to a Paragraph IV filing strategy.
Run a freedom-to-operate analysis on US11298349B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA cabozantinib and kinase inhibitor patent cases in Delaware
Explore comparable Hatch-Waxman patent infringement cases involving oncology small molecules and ANDA challenges adjudicated in the Delaware District Court.
What this case signals for the oncology ANDA IP landscape
A plaintiff win on three of four patents — with zero invalidity successes for the generic — illustrates the defensive power of layered patent portfolios in pharmaceutical litigation.
Multi-claim portfolio strategy effectively extended CABOMETYX® exclusivity
Exelixis asserted four patents with specific dependent claims, ensuring that even a partial loss on one patent (the ‘349 infringement claim) left the injunction intact. Branded pharma teams should audit whether their ANDA-listed patents are similarly layered — if one claim falls, the commercial protection must still hold through other asserted claims.
Invalidity counterclaims failed across all four patents — a strong signal for patent quality
MSN raised invalidity challenges against all four asserted patent claims and lost every one. This outcome, consistent with the high bar for invalidity in Hatch-Waxman trials, suggests Exelixis’ prosecution strategy produced claims with robust prior-art and enablement foundations. Generic challengers should conduct deeper pre-filing invalidity analysis before committing to Paragraph IV strategies against well-prosecuted pharma portfolios.
Exelixis v MSN — key questions answered
Final judgment was entered in favor of Exelixis on October 23, 2024. The Delaware District Court found MSN’s ANDA product infringed claim 4 of the ‘439 patent, claim 3 of the ‘440 patent, and claim 2 of the ‘015 patent. MSN is permanently enjoined from commercializing its generic cabozantinib product until January 15, 2030. MSN prevailed only on the infringement claim for the ‘349 patent, but all invalidity counterclaims failed.
Exelixis asserted four patents in this Hatch-Waxman infringement action, with the case record identifying US11298349B2 (application US17/170275) as one of the patents-in-suit. The verdict references the ‘439, ‘440, ‘015, and ‘349 patents, all covering aspects of cabozantinib (S)-malate compositions and use. Three of the four asserted patents were found infringed by MSN’s ANDA No. 213878 product.
Under the final judgment, the FDA cannot grant final approval to MSN’s ANDA No. 213878 before January 15, 2030 — the expiry date of the ‘439, ‘440, and ‘015 patents, including any extensions or exclusivity periods. MSN and its transferees are permanently enjoined from commercial manufacture, sale, or importation of the generic product in the U.S. until that date. This timeline could extend further if any patent term extensions are granted.
MSN succeeded on one infringement claim: the court found that its ANDA product did not infringe claim 3 of the ‘349 patent under 35 U.S.C. § 271(e)(2). However, MSN failed on all invalidity counterclaims — all four asserted patent claims, including the ‘349 patent’s claim 3, were upheld as valid. The practical commercial outcome for MSN was unchanged; the injunction based on the three other patents still blocks generic launch until 2030.
The verdict signals that Exelixis’ cabozantinib patent portfolio is both robust and strategically structured to withstand invalidity challenges in Hatch-Waxman litigation. Other ANDA filers considering a Paragraph IV challenge against CABOMETYX® will face the same multi-patent barrier through at least 2030. The ‘349 non-infringement finding suggests narrow formulation-based design-around strategies may exist, but any new ANDA will need thorough claim-by-claim FTO analysis before filing.
PatSnap Eureka searches patents and litigation data to answer instantly.